Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure

Clinical Chemistry and Laboratory Medicine

Volumn 44, Issue 1, 2006, Pages 64-69

  Kimak, Elzbieta ^a   Ksia̧zek, Andrzej ^a   Solski, Janusz ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Composition; Failure; Lipids; Lipoproteins; Renal

Indexed keywords

ANTIBODY; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC KIT; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DYSLIPIDEMIA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LINEAR REGRESSION ANALYSIS; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID COMPOSITION; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SEPARATION TECHNIQUE; VARIANCE;

HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIPOPROTEINS; PERITONEAL DIALYSIS; RENAL DIALYSIS;

EID: 29444454614     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2006.013     Document Type: Article

References (17)

1. Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the Atherosclerosis Risk in Communities study. Kidney Int 2000;58:293-301.
2. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000;102:1886-92.
3. Rutkowski B, Szolkiewicz M, Korczyńska J, Sucajtys E, Stelmańska E, Nieweglowski T, et al. The role of lipogenesis in the development of uremic hyperlipidemia. Am J Kidney Dis 2003;41(Suppl 1):S84-8.
4. Kimak E, Solski J. ApoA- and ApoB-containing lipoproteins and Lp(a) concentration in non-dialized patients with chronic renal failure. Ren Fail 2002;24:481-8.
5. Kimak E, Solski J, Janicka L, Ksia̧żek A, Janicki K. Concentration of Lp(a) and other apolipoproteins in predialysis, hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients. Clin Chem Lab Med 2000;38:421-5.
6. Moberly JB, Attman P-O, Samuelsson O, Johansson A-C, Knight-Gibson C, Alaupovic P. Apolipoprotein CIII, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia. Miner Electrolyte Metab 1999;25:258-62.
7. Lee DM, Knight-Gibson C, Samuelsson O, Attman P-O, Wang C-S, Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002;61:209-18.
8. Samuelsson O, Attman P-O, Knight-Gibson C, Larsson R, Mulec H, Weiss HA, et al. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. J Am Soc Nephrol 1998;9:1482-8.
9. Attman P-O, Samuelsson JM, Moberly J, Johansson A-C, Ljungman S, Weiss LG, et al. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int 1999;55:1536-42.
10. Lee S-J, Moye LA, Campos H, Williams GH, Sacks FM. Hypertriglyceridemia but not diabetes status is associated with VLDL-containing apolipoprotein CIII in patients with coronary heart disease. Atherosclerosis 2003;167:293-302.
11. Santo SMS, Rensen PCN, Goudriaan JR, Bensadoun A, Bovenschen N, Voshol PJ, et al. Triglyceride-rich lipoprotein metabolism in unique VLDL receptor, LDL receptor, and LRP triple-deficient mice. J Lipid Res 2005;46:1097-102.
12. Prinsen BH, Rabelink TJ, Romijn JA, Bisschop PH, De Barse MM, Boer J, et al. A broad-based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int 2004;65:1064-75.
13. Schreier L, Gonzalez Al, Elbert A, Berg G, Wikinski R. Utility of non-high-density lipoprotein cholesterol in hemodialyzed patients. Metabolism 2004;53:1013-5.
14. Huard K, Bourgeois P, Rhainds D, Falstrault L, Cohn JS, Brissette L. Apolipoproteins C-II and C-III inhibit selective uptake of low- and high-density lipoprotein cholesteryl esters in HepG2 cells. Int J Biochem Cell Biol 2005;37:1308-18.
15. Charpentier D, Tremblay C, Rassart E, Rhainds D, Auger A, Milne RW, et al. Low- and high-density lipoprotein metabolism in HepG2 cells expressing various levels of apolipoprotein E. Biochemistry 2000;39:16084-91.
16. Okubo K, Ikewaki K, Sakai S, Tada N, Kawaguchi Y, Mochizuki S. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J Am Soc Nephrol 2004;15:1008-15.
17. Lee J-Y, Lanningham-Foster L, Boudyguina EY, Smith TL, Young ER, Colvin PL, et al. Preβ high density lipoprotein has two metabolic fates in human apolipoprotein A-I transgenic mice. J Lipid Res 2004;45:716-28.